Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Inclusion Criteria: * 18 years of age and older * Histological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, primary peritoneal carcinoma, or papillary serous mullerian carcinoma * Previous attempted surgical debulking * Stage III or IV * Willing and able to undergo second look laparoscopy * Performance status 0-1 by ECOG scale * Peripheral neuropathy \< grade 2 * Life expectancy of 6 months or greater Exclusion Criteria: * Patients with clinically significant cardiovascular disease as outlined in the protocol * Neutrophil count \< 1,500/mm3; platelet count \<100,000/m3 * Alkaline phosphatase or bilirubin \> 1.5 x ULN, SGOT \> 5 x ULN * Calculated creatinine clearance \< 50ml/min * Prior chemotherapy or radiotherapy for other malignancy except for the treatment for localized breast cancer greater than five years prior to diagnosis * No more than one cycle of first line chemotherapy with carboplatin and paclitaxel * Inadequate surgical cytoreduction such that interval cytoreductive surgery could materially improve prognosis * Concurrent invasive malignancy * Evidence of bleeding diathesis or coagulopathy * Evidence of tumor involving major blood vessels on any prior CT scans * Surgical wound that has failed to close * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of this study * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to day 0 * Serious non-healing wound, ulcer, or bone fracture * Prior treatment with an anti-angiogenic agent * Any active bleeding * Active psychiatric disease or neurologic symptoms requiring treatment * Presence of central nervous system brain metastases * Proteinuria at screening as demonstrated by criteria in protocol * Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent * Known hypersensitivity to Cremophor EL or any component of Avastin * Active bacterial, viral, or fungal infections * Receiving any other investigational agent * History of gastrointestinal perforation * Prior therapies targeting the epidermal growth factor receptor * Symptoms of bowel obstruction * Dependence on TPN or IV hydration